Centro de Investigaciones Metabólicas (CINME)
Buenos Aires, Argentina
7 recruiting
Showing 1–7 of 7 trials
Recruiting
Phase 3
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
DementiaBrain DiseasesCentral Nervous System Diseases+6 more
Eli Lilly and Company1,500 enrolled141 locationsNCT05508789
Recruiting
Phase 3
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
ObesityOverweight
Eli Lilly and Company600 enrolled35 locationsNCT07357415
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
ObesityOverweight
Eli Lilly and Company1,035 enrolled158 locationsNCT07282600
Recruiting
Phase 2
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
Asthma
Eli Lilly and Company531 enrolled121 locationsNCT07219173
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Chronic Kidney DiseaseAtherosclerosis Cardiovascular Disease
Eli Lilly and Company7,140 enrolled565 locationsNCT07241390
Recruiting
Phase 2
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
ObesityDiabetes Mellitus, Type 2Overweight
Eli Lilly and Company200 enrolled38 locationsNCT07215559
Recruiting
Phase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Asthma
Pfizer252 enrolled125 locationsNCT06977581